Celgene to buy Juno for $9 billion to boost cancer pipeline

(Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid.

Source: Reuters: Health - January 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news